Prescription drug access and pricing have been in the policy spotlight at the federal level over the past few years, with Congress taking unprecedent steps to respond to high prescription drug prices in Medicare through passage of the Inflation Reduction Act (IRA) in 2022. But state governments are also finding ways to address the rising costs of drugs. One mechanism states are using to evaluate and curb the prices of certain high-cost drugs are Prescription Drug Affordability Boards (PDABs). A PDAB is an independent board made up of experts tasked with analyzing—and in some cases, acting to reduce—high drug prices in the state. Read on to learn more about PDABs and how their decisions may impact individuals who rely on high-cost medications to stay healthy.
Read the latest Health Care in Motion.
Health Law & Policy, Commentary
Addressing The HIPAA Blind Spot For Crisis Pregnancy Centers
November 18, 2024